Evidence map›Paper›PMID 38254626›Full record

ArticleBiomolecules2023

Evidence of Guanidines Potential against

Luana Ribeiro Dos Anjos, Vanessa Maria Rodrigues de Souza, Yasmim Alves Aires Machado, Vitor Moreira Partite, Mohammed Aufy, Geovane Dias Lopes, Christian Studenik, Carlos Roberto Alves, Gert Lubec, Eduardo Rene Perez Gonzalez and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Luana Ribeiro Dos AnjosFine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University (UNESP), Presidente Prudente 19060-080, Brazil.ORCID 0000-0002-2487-6176
Vanessa Maria Rodrigues de SouzaInfectious Disease Laboratory-LADIC, Federal University of Parnaíba Delta-UFDPar, Campus Ministro Reis Velloso, São Benedito, Parnaíba 64202-020, Brazil.
Yasmim Alves Aires MachadoInfectious Disease Laboratory-LADIC, Federal University of Parnaíba Delta-UFDPar, Campus Ministro Reis Velloso, São Benedito, Parnaíba 64202-020, Brazil.
Vitor Moreira PartiteFine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University (UNESP), Presidente Prudente 19060-080, Brazil.
Mohammed AufyDepartment of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Josef Holaubek Platz 2, UZAII (2D 259), 1090 Vienna, Austria.ORCID 0000-0002-6693-4530
Geovane Dias LopesLaboratório de Biologia Molecular e Doenças Endêmicas, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0003-4448-1398
Christian StudenikDepartment of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Josef Holaubek Platz 2, UZAII (2D 259), 1090 Vienna, Austria.ORCID 0000-0002-0910-4573
Carlos Roberto AlvesLaboratório de Biologia Molecular e Doenças Endêmicas, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, 4365, Manguinhos, Rio de Janeiro 21040-900, Brazil.
Gert LubecDepartment of Neuroproteomics, Paracelsus Medical University, 5020 Salzburg, Austria.ORCID 0000-0002-6333-9461
Eduardo Rene Perez GonzalezFine Organic Chemistry Lab, School of Sciences and Technology, São Paulo State University (UNESP), Presidente Prudente 19060-080, Brazil.ORCID 0000-0003-1348-8554
Klinger Antonio da Franca RodriguesInfectious Disease Laboratory-LADIC, Federal University of Parnaíba Delta-UFDPar, Campus Ministro Reis Velloso, São Benedito, Parnaíba 64202-020, Brazil.ORCID 0000-0003-3904-3529
Universidade Estadual Paulista (Unesp) · BRFundação Oswaldo Cruz · BRUniversity of Vienna · ATParacelsus Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a complex group of infectious and parasitic diseases that afflict many thousands of individuals across five continents. Leishmaniasis treatment remains a challenge because it relies on drugsknown for their high toxicity and limited efficacy, making itimperative to identify new molecules that offer greater effectiveness and safety. This study sought to explore the impact of seven synthetic guanidine derivatives (LQOF-G1, LQOF-G2, LQOF-G6, LQOF-G7, LQOF-G32, LQOF-G35 and LQOF-G36) onthe parasite

Indexed as

Leishmania braziliensisLeishmaniasisAnimalsCaco-2 CellsGuanidineGuanidinesHEK293 CellsHumansImmunity, InnateMammalsGuanidineGuanidinesguanidine derivativesimmunomodulationLeishmania (Viannia) braziliensisorgan and cell toxicity

Identifiers

PMID38254626
PMCPMC10813298
OpenAlexW4390176315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.